2.39
-0.32 (-11.81%)
| Penutupan Terdahulu | 2.71 |
| Jumlah Dagangan | 313,461 |
| Harga / Jualan (P/S) | 5.52 |
| Harga / Buku (P/B) | 0.830 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,359.84% |
| EPS Cair (TTM) | -1.35 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.55% |
| Nisbah Semasa (MRQ) | 5.61 |
| Aliran Tunai Operasi (OCF TTM) | -15.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.69 M |
| Pulangan Atas Aset (ROA TTM) | -72.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -167.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Longeveron Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.45% |
| % Dimiliki oleh Institusi | 8.78% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |